We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.44%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$553M
AUM Growth
+$22M
Cap. Flow
-$5.91M
Cap. Flow %
-1.07%
Top 10 Hldgs %
30.71%
Holding
131
New
7
Increased
28
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.16M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$4.22M
3
AKRX
Akorn Inc
AKRX
+$3.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.21M
5
ENDP
Endo International plc
ENDP
+$2.74M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$6.62M
2
CAH icon
Cardinal Health
CAH
+$6.02M
3
MDVN
MEDIVATION, INC.
MDVN
+$4.7M
4
STJ
St Jude Medical
STJ
+$4.68M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 92.11%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMH
101
DELISTED
Team Health Holdings Inc
TMH
$814K 0.15%
25,000
+10,000
+67% +$369K
GWPH
102
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$796K 0.14%
+6,000
New +$573K
NVRO
103
DELISTED
NEVRO CORP.
NVRO
$783K 0.14%
7,500
– –
AAC
104
DELISTED
AAC Holdings
AAC
$783K 0.14%
45,000
– –
KITE
105
DELISTED
Kite Pharma, Inc.
KITE
$782K 0.14%
14,000
– –
EXEL icon
106
Exelixis
EXEL
$14.1B
$767K 0.14%
60,000
-110,000
-65% -$1.19M
UTHR icon
107
United Therapeutics
UTHR
$22.7B
$744K 0.13%
6,300
– –
VAR
108
DELISTED
Varian Medical Systems, Inc.
VAR
$697K 0.13%
7,983
-14,825
-65% -$1.21M
NVAX icon
109
Novavax
NVAX
$1.35B
$676K 0.12%
16,250
– –
TBPH icon
110
Theravance Biopharma
TBPH
$877M
$668K 0.12%
18,428
+7,000
+61% +$195K
DVA icon
111
DaVita
DVA
$15.2B
$661K 0.12%
10,000
-3,000
-23% -$211K
CLDX icon
112
Celldex Therapeutics
CLDX
$2.77B
$646K 0.12%
10,667
– –
PODD icon
113
Insulet
PODD
$11.4B
$614K 0.11%
15,000
– –
ESPR
114
DELISTED
Esperion Therapeutics
ESPR
$554K 0.1%
40,000
– –
RMD icon
115
ResMed
RMD
$28.9B
$518K 0.09%
8,000
– –
PEN icon
116
Penumbra
PEN
$12.5B
$380K 0.07%
5,000
– –
WBMD
117
DELISTED
WebMD Health Corp.
WBMD
$368K 0.07%
+7,400
New +$408K
SGRY icon
118
Surgery Partners
SGRY
$2.09B
$304K 0.05%
15,000
– –
MYGN icon
119
Myriad Genetics
MYGN
$584M
$288K 0.05%
14,000
– –
QHC
120
DELISTED
Quorum Health Corporation
QHC
$78K 0.01%
12,500
– –
EIGR
121
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$45K 0.01%
111
– –
CYH icon
122
Community Health Systems
CYH
$465M
– –
-50,000
Closed -$603K
LRMR icon
123
Larimar Therapeutics
LRMR
$384M
– –
-1,667
Closed -$120K
SUPN icon
124
Supernus Pharmaceuticals
SUPN
$2.79B
– –
-164,000
Closed -$3.34M
THC icon
125
Tenet Healthcare
THC
$16.8B
– –
-10,000
Closed -$276K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2016 Portfolio in Review

As of Q3 2016, Bellevue Group held 131 positions worth $553M, up 4.1% from $531M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group's Q3 2016 filing shows 7 new, 28 increased, 30 reduced and 10 closed positions. Its largest new stake was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M. The largest sale was CVS Health, an estimated $6.62M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials.

  • Bellevue Group's largest Q3 2016 buy was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M.
  • Bellevue Group added most to Viatris in Q3 2016, an estimated $5.16M increase.
  • Bellevue Group's biggest Q3 2016 reduction was CVS Health, cutting an estimated $6.62M.
  • Bellevue Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $4.7M.
  • Bellevue Group's ten largest holdings make up 31% of its $553M portfolio in Q3 2016.
  • Bellevue Group opened 7 new positions and closed 10 in Q3 2016.
  • Bellevue Group's portfolio value rose 4.1% quarter-over-quarter to $553M.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.